16 Mar 2020
COVID-19 - Business Continuity Plan Activation
Following recent developments and immediately after WHO announcement of COVID-19 virus outbreak classification as a pandemic, OWLPHARMA has decided to activate its business continuity plan.
21 Feb 2020
Safety Assessment of Cosmetic Products
Regulation (EC) no. 1223/2009 stipulates that all cosmetic products, prior to being marketed in the EU, must undergo a safety assessment carried out by a qualified person. The assessment must always be kept up to date, and any relevant information generated after the product is placed on the market has to be taken into account.
6 Feb 2020
Estamos a recrutar - Medical Writer
A OWLpharma tem em aberto uma vaga para Medical Writer no Departamento Médico-Científico, em Coimbra.
21 Jan 2020
Nitrosamines – Risk evaluation
At the end of September EMA began a review under the Article 5(3) of Regulation (EC) No 726/2004 to provide guidance for MAHs on how to avoid nitrosamines in human medicines.
21 Jan 2020
GMP for Medicinal Cannabis – 29th of January
André Luz, the Director of Quality Assurance at Owlpharma, will be presenting a “GMP for Medicinal Cannabis” training on January 29th in collaboration with Formiventos.